Only one way to acquiring market authorization according to NiCE and EMA alzheimer's disease guidelines is the biomarker targeted treatment. Because the agency has required the mean difference score 1.63 CDR -SB score in early alzheimer's disease which is clinical meaningful score ,but any drug around world is not possible. Anavex company has known this guidelines, therefore company has focused on responder group that maybe high SIGMAR-1 mRNA level among the anavex2-73 treatment patients (30 or 50) Only anavex2-73 responder group can meet to required score of NICE and EMA We saw the possibility of them at 2022 CATD
Market Data 
Markets 
